Increased risk of second malignancies after in situ breast carcinoma in a population-based registry

Soerjomataram, I.; Louwman, W. J.; van der Sangen, M. J. C.; Roumen, R. M. H.; Coebergh, J. W. W.
August 2006
British Journal of Cancer;8/7/2006, Vol. 95 Issue 3, p393
Academic Journal
Among 1276 primary breast carcinoma in situ (BCIS) patients diagnosed in 1972–2002 in the Southern Netherlands, 11% developed a second cancer. Breast carcinoma in situ patients exhibited a two-fold increased risk of second cancer (standardised incidence ratios (SIR): 2.1, 95% confidence interval (CI): 1.7–2.5). The risk was highest for a second breast cancer (SIR: 3.4, 95% CI: 2.6–4.3; AER: 66 patients per 10 000 per year) followed by skin cancer (SIR: 1.7, 95% CI: 1.1–2.6; AER: 17 patients per 10 000 per year). The increased risk of second breast cancer was similar for the ipsilateral (SIR: 1.9, 95% CI: 1.3–2.7) and contralateral (SIR: 2.0, 95% CI: 1.4–2.8) breast. Risk of second cancer was independent of age at diagnosis, type of initial therapy, histologic type of BCIS and period of diagnosis. Standardised incidence ratios of second cancer after BCIS (SIR: 2.3, 95% CI: 1.8–2.8) resembled that after invasive breast cancer (SIR: 2.2, 95% CI: 2.1–2.4). Surveillance should be directed towards second (ipsi- and contra-lateral) breast cancer.British Journal of Cancer (2006) 95, 393–397. doi:10.1038/sj.bjc.6603231 www.bjcancer.com Published online 27 June 2006


Related Articles

  • Contralateral Second Breast Cancers: Prediction and Prevention. Brenner, David J. // JNCI: Journal of the National Cancer Institute;4/7/2010, Vol. 102 Issue 7, p444 

    The author addresses the prediction and prevention of contralateral second breast cancer. Results of long-term studies showed that contralateral second breast cancer rates range from 10 percent to 15 percent at 15 years after cancer therapy. Researchers found that the possibility of a breast...

  • 8th European Breast Cancer Conference (EBCC-8): Cancer cells in blood predict chances of survival and can help target breast cancer treatment.  // Biomedical Market Newsletter;3/28/2012, Vol. 21, p1 

    The article focuses on a research, according to which breast cancer patients with at least five circulating tumor cells in their blood detected straight after surgery have a four-fold increase in the risk of recurrence and a three-fold increase in the risk of death.

  • Validation of a Breast Cancer Risk Prediction Model Developed for Black Women. Boggs, Deborah A.; Rosenberg, Lynn; Pencina, Michael J.; Adams-Campbell, Lucile L.; Palm, Julie R. // JNCI: Journal of the National Cancer Institute;3/6/2013, Vol. 105 Issue 5, p361 

    Background A breast cancer risk prediction model for black women, developed from data in the Women's Contraceptive and Reproductive Experiences (CARE) study, has been validated in women aged 50 years or older but not among younger women or for specific breast cancer subtypes. Methods We assessed...

  • BRCA1 mutation increased risk for rare uterine cancers after salpinqo-oophorectomy. Todak, Alexandra // Hem/Onc Today;4/25/2014, Vol. 15 Issue 8, p16 

    The article discusses the prospective cohort study that found increased risk for women who harbor breast cancer one, early onset (BRCA1) mutations to develop rare, aggressive forms of uterine cancer after they undergo risk-reducing salpingo-oophorectomy.

  • Breast Cancer Survivorship Care: Targeting a Colorectal Cancer Education Intervention. Homan, Sherri G.; Shumei Yun; Stewart, Bob R.; Armer, Jane M. // Journal of Personalized Medicine;2015, Vol. 5 Issue 3, p296 

    Breast cancer survivors are at risk of developing a second primary cancer. Colorectal cancer (CRC) is one of the leading second primary cancers, and it is often preventable. We developed a multi-component educational tool to inform and encourage women breast cancer survivors to engage in CRC...

  • The choice no woman wants to make. Pollak, Suzanne // Washington Jewish Week;10/3/2013, Vol. 49 Issue 40, p1 

    The article reflects on the increased chances of being diagnosed with mutated BRCA1 or BRCA2 gene that can causes breast cancer or ovarian cancer in Jewish women from Ashkenazi heritage. It informs about the program titled "Hereditary Cancer: Knowledge is Power" organized at the Jewish Community...

  • Breast Cancer Under Forty. Miller, Doriane C. // Chicago Citizen - Chicago Weekend Edition;11/20/2013, Vol. 43 Issue 46, p2 

    In this article, the author presents precautions against breast cancer for African –American women under the age of fourty. She mentions that African-American women exhibit particular genetic mutation which increases the chance of breast cancer disease among them. She suggests that women...

  • Pedigree studies and evaluation of risk factors of breast cancer in Goa. Fernandes, N. V.; Pinto, S.; Dias, P.; Kolwalkar, D.; Chipkar, T. // Indian Journal of Cancer;Oct-Dec2014, Vol. 51 Issue 4, p600 

    Background: Incidence of breast cancer (BC) is increasing in most of the countries, including the areas which have had previously low rates.Aim: The aim of this prospective study was to analyze the pedigrees of the patients for detecting hereditary factor prevalence and...

  • CD44 rs13347 C>T polymorphism predicts breast cancer risk and prognosis in Chinese populations. Lan Jiang; Jieqiong Deng; Xun Zhu; Jian Zheng; Yonghe You; Na Li; Hongchun Wu; Jiachun Lu; Yifeng Zhou // Breast Cancer Research;2012, Vol. 14 Issue 4, p1 

    Introduction: It has been demonstrated that the interplay of adhesion molecule CD44 and its ligands can regulate cancer cell proliferation, migration and invasion, as well as tumor-associated angiogenesis and is related to breast cancer patient survival. In this two-stage, case control study, we...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics